Boston Scientific EV/EBIT BSX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Oct 23, 2026: 18.2×
10-year median: 42.0×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 17.2× to 95.1×
Peer median: 23.4×

Boston Scientific's EV/EBIT is 18.2× as of Oct 23, 2026.

That is below its ten-year median of 42.0×, lower than on 99% of days in the last ten years.

Over that time it ranged from 17.2× in Oct 2026 to 95.1× in Apr 2021.

The median for 7 medical device stocks of a similar size is 23.4×.

EV/EBIT over time

median 42×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	18.2×	17.2×	44.7×
2025	44.0×	42.6×	55.2×
2024	47.6×	43.2×	51.0×
2023	43.0×	38.7×	50.2×
2022	46.4×	33.3×	46.7×
2021	41.6×	38.1×	95.1×
2020	77.1×	29.6×	80.9×
2019	45.3×	35.7×	45.4×
2018	36.1×	32.4×	39.8×
2017	32.1×	32.1×	38.6×
2016	33.3×	31.7×	49.1×
2015	43.7×	29.4×	44.4×
2014	29.3×	4.3×	106×
2013	4.4×	3.6×	5.8×
2012	34.7×	4.7×	37.4×
2011	4.7×	4.6×	11.3×
2010	11.3×	10.0×	11.5×

Against its peers

Companies in Medical - Devices nearest Boston Scientific's size, closest first, today.

Company	EV/EBIT
BSXBoston Scientific	18.2×
EWEdwards Lifesciences	23.5×
SYKStryker	23.4×
MDTMedtronic	20.7×
GEHCGE HealthCare Technologies	14.7×
DXCMDexCom	25.3×
ABTAbbott Laboratories	28.2×
ZBHZimmer Biomet	21.5×
Peer median	23.4×

Where Boston Scientific ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Boston Scientific

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.